Clinical Trial Update: Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Rituximab, Eltrombopag, and Dexamethasone as frontline therapy for immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Eltrombopag (eltrombopag)
• Rituximab (rituximab)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN